# Empagliflozin in Diuretic Refractory Ascites

> **NCT05013502** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 14 (actual)

## Conditions studied

- Liver Cirrhosis
- Cirrhosis
- Ascites
- Ascites Hepatic
- Sodium-Glucose Transporter 2 Inhibitors

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT05013502
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-15
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013502, "Empagliflozin in Diuretic Refractory Ascites". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05013502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*